Lucrin Depot11.25 mg

Lucrin Depot is a synthetic gonadotropin-releasing hormone (GnRH) agonist used across oncology, gynecology, and pediatric endocrinology. Indications are classified below by strength of evidence.

Established / Approved Uses

• Advanced prostate cancer — palliative treatment to reduce testosterone to castrate levels, alone or in combination with radiation therapy or an anti-androgen.
• Endometriosis — management of pelvic pain and associated symptoms, typically for a limited duration (up to 6 months), with or without "add-back" hormone therapy.
• Uterine fibroids (leiomyomata) — short-term use (generally with concomitant iron therapy) to reduce fibroid size and correct anemia before surgery.
• Central precocious puberty (CPP) — suppression of pubertal hormone secretion in children who meet diagnostic criteria, under pediatric endocrinology supervision.

Adjunct / Combination Uses

• Used together with an anti-androgen during the first weeks of prostate cancer treatment to blunt the initial testosterone "flare."
• Used with norethindrone acetate "add-back" therapy in endometriosis to reduce bone mineral density loss during extended courses.

Off-Label / Guideline-Supported Uses

• Pituitary down-regulation in assisted reproductive technology (ART) / controlled ovarian stimulation protocols.
• Ovarian suppression for fertility preservation during chemotherapy, and in selected premenopausal breast cancer treatment protocols.
• Puberty suppression in adolescents with gender dysphoria (specialist-supervised, off-label).

Lucrin Depot is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH). It belongs to the class of GnRH agonists and is formulated as a long-acting depot injection administered subcutaneously or intramuscularly.

With continuous administration, Lucrin Depot produces sustained suppression of pituitary gonadotropin (LH and FSH) secretion, leading to markedly reduced testosterone levels in men and estradiol levels in women, which forms the basis of its therapeutic effect in hormone-dependent conditions.

Lucrin Depot belongs to the GnRH (Gonadotropin-Releasing Hormone) Agonist class, also categorized as an antineoplastic hormonal agent.

Leuprorelin Acetate is a potent agonist analog of GnRH. Following an initial injection, it transiently stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), producing a temporary rise in testosterone (men) or estrogen (women) — known as the "flare" phenomenon — within the first 1–2 weeks.

With continued, uninterrupted dosing, GnRH receptors on pituitary gonadotrophs become desensitized and down-regulated, resulting in sustained suppression of LH and FSH secretion. This drives testosterone in men down to castrate levels (typically within 2–4 weeks) and suppresses estradiol in women to postmenopausal-range concentrations, and suppresses gonadal steroid production in children with central precocious puberty.

Lucrin Depot depot injection is prepared and administered only by a trained healthcare professional. Powder formulations are reconstituted with the accompanying diluent immediately before injection and given by subcutaneous or intramuscular route, rotating injection sites. Prefilled syringe formulations are used as supplied. The injection must not be self-administered at home.

Clinically significant interactions with Lucrin Depot include:

• QT-prolonging drugs (e.g., Class IA and III antiarrhythmics such as quinidine, procainamide, sotalol, amiodarone): androgen-deprivation therapy with Lucrin Depot itself can prolong the QT interval; concurrent use with other QT-prolonging drugs may increase the risk of clinically significant arrhythmia and should be avoided or closely monitored.
• Drugs affecting pituitary-gonadal function (e.g., other hormonal therapies, estrogens, androgens): may interfere with the intended hormonal suppression and are generally avoided during treatment unless specifically prescribed as add-back therapy.
• Antidiabetic agents: Lucrin Depot can reduce glucose tolerance; blood glucose monitoring and dose adjustment of antidiabetic drugs may be needed.

Common side effects of Lucrin Depot relate to the induced hypogonadal state and include:

• Hot flashes/flushes and sweating
• Injection site reactions (pain, redness, induration)
• Headache and mood changes
• Decreased libido and, in men, erectile dysfunction, gynecomastia
• In women, vaginal dryness and initial spotting/vaginal bleeding
• Bone mineral density reduction with prolonged use
• Transient worsening of prostate cancer symptoms (bone pain, urinary symptoms) or endometriosis symptoms during the initial "flare" — see Precautions and Warnings

Lucrin Depot is contraindicated in pregnancy for gynecologic and pediatric indications, as it may cause fetal harm based on its mechanism of action and animal data. Pregnancy should be excluded before starting treatment for these indications, and effective non-hormonal contraception should be used during therapy.

Lucrin Depot is not recommended during breastfeeding; because of the potential for adverse effects on hormone-dependent processes, women should consult their physician regarding breastfeeding while receiving Lucrin Depot. Use only if clearly needed and the potential benefit justifies the potential risk, and always under specialist supervision.

Initial flare: During the first 1–2 weeks of Lucrin Depot therapy, a transient rise in testosterone or estrogen can temporarily worsen prostate cancer symptoms (bone pain, spinal cord compression, urinary tract obstruction) or endometriosis symptoms. A short course of an anti-androgen may be used concurrently in men at risk of these complications.

Bone mineral density loss: Prolonged suppression of sex steroids reduces bone density; this is a particular concern with extended courses for endometriosis or fibroids and may warrant monitoring or add-back therapy, while in prostate cancer the oncologic benefit generally outweighs this risk.

Cardiovascular risk: QT/QTc prolongation and increased cardiovascular event risk have been reported in men receiving Lucrin Depot for prostate cancer; cardiovascular risk factors should be assessed and managed, with ECG monitoring in high-risk patients.

Metabolic effects: Hyperglycemia, worsening of diabetes, and changes in lipid profile may occur; monitor blood glucose periodically.

Psychiatric and neurologic effects: Mood changes, depression, and rare cases of seizures/convulsions and pituitary apoplexy have been reported; use with caution in patients with a seizure disorder or pituitary tumor.

Hormone-suppression symptoms: Hot flashes and other menopausal-type symptoms are an expected consequence of therapy and should be discussed with patients in advance.

There is limited clinical experience with overdose of Lucrin Depot. In case of suspected overdose, seek immediate medical attention or contact a poison control center / emergency services. Management is supportive and symptomatic; there is no specific antidote. Discontinuation of the drug and close monitoring of hormonal and clinical status is advised under medical supervision.

Store as directed on the product label; most depot kits require storage at controlled room temperature (below 30°C) or refrigeration (2°C–8°C) depending on the specific formulation — check the manufacturer's instructions. Protect from light and moisture. Once reconstituted, use immediately and do not store the prepared suspension. Keep out of reach of children.

Renal impairment: No specific dose adjustment is well established for Lucrin Depot; use with caution and monitor clinical response.

Hepatic impairment: No specific dose adjustment is well established; use with caution.

Elderly: Commonly used in this population for prostate cancer; no specific dose adjustment required based on age alone, but cardiovascular and metabolic monitoring is advised.

Pediatric patients: See Pediatric Uses.

Pregnant/lactating women: See Pregnancy and Lactation.

Duration of Lucrin Depot therapy is indication-specific: prostate cancer treatment is typically long-term/ongoing as directed by an oncologist; endometriosis treatment is generally limited to about 6 months (without add-back therapy) due to bone density concerns; uterine fibroid treatment is usually limited to about 3 months before surgery; central precocious puberty treatment continues until an appropriate age for normal pubertal progression, as determined by a pediatric endocrinologist.

Depot (sustained-release) formulations of Lucrin Depot are supplied as a lyophilized microsphere powder that must be reconstituted with the diluent provided in the manufacturer's kit immediately before subcutaneous or intramuscular injection. The powder and diluent should be mixed gently to form a uniform suspension exactly as described in the product's instructions for use, and the reconstituted suspension must be administered immediately — it should not be stored for later use.

GnRH Agonist; Antineoplastic Hormonal Agent; Gonadotropin Inhibitor

Leuprorelin Acetate is a synthetic decapeptide analog of GnRH that binds pituitary GnRH receptors. Initial administration causes transient stimulation of LH/FSH release ("flare"), followed within 2–4 weeks of continuous dosing by receptor down-regulation and desensitization, producing sustained suppression of LH and FSH. This lowers testosterone in men and estradiol in women to castrate/postmenopausal levels, and suppresses gonadal steroidogenesis in children with central precocious puberty, underlying its use in hormone-dependent conditions.

X

Lucrin Depot is approved for the treatment of central precocious puberty (CPP) in children who meet diagnostic criteria, using weight-based or age-appropriate depot dosing under the supervision of a pediatric endocrinologist, with periodic monitoring of growth, bone age, and hormonal suppression.

Use of Lucrin Depot for other pediatric purposes (e.g., puberty suppression in adolescents with gender dysphoria) is considered off-label; safety and efficacy for such uses have not been formally established in the approved labeling, and treatment should occur only under specialist multidisciplinary supervision.